demonstrated that semaglutide modulates the circulating proteome in individuals with overweight or obesity, with or without diabetes [67]
But I pushed through because I could already see where this was heading
For tirzepatide, CVOTs are still not published
For the injectable GLP-1 RAs, this shouldnt be much of an issue, as the companys dosing aligns nicely with the research
At an annual cost of ~17K, this once-weekly injection offers a convenient option for adults with obesity (BMI 30) or those who are overweight (BMI 27) with related health conditions, helping them achieve and maintain weight loss
Reported shares: side effects 36 percent, logistical challenges 24 percent, cost 23 percent, supply shortages 11 percent, dissatisfaction with weight loss 7 percent